GILD•benzinga•
Reported Saturday, Gilead's TROP-2 ADC Trodelvy, In Combination With Keytruda, Shows Clinically Meaningful Survival Gains And Fewer Adverse Event-Related Discontinuations In ASCENT-04
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga